Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
MagForce continues to implement its two-pillar strategy. A gross $9.0m capital raise secured by subsidiary MagForce USA in August will enable financing of the pivotal US prostate cancer trial to completion. In Europe, expansion outside Germany has started and a NanoActivator will be installed in Poland by the end of the year. Of the €9.2m reported revenue and other operating income in H118, €24k relates to EU glioblastoma multiforme (GBM) treatments, while the remainder (€8.9m) was one-off, non-cash income relating to hidden reserves as a result of the MagForce USA shares transfer. Revenues are likely to pick up in 2019, following the roll-out of devices across Europe and a launch in the US (in late 2019).
Written by
MagForce |
2019 a pivotal year
Healthcare equipment |
Scale research report - Update
7 November 2018 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts. |
||||||||||||||||||||||||||||||
MagForce continues to implement its two-pillar strategy. A gross $9.0m capital raise secured by subsidiary MagForce USA in August will enable financing of the pivotal US prostate cancer trial to completion. In Europe, expansion outside Germany has started and a NanoActivator will be installed in Poland by the end of the year. Of the €9.2m reported revenue and other operating income in H118, €24k relates to EU glioblastoma multiforme (GBM) treatments, while the remainder (€8.9m) was one-off, non-cash income relating to hidden reserves as a result of the MagForce USA shares transfer. Revenues are likely to pick up in 2019, following the roll-out of devices across Europe and a launch in the US (in late 2019).
NanoTherm US prostate cancer trial funding secured
In August 2018, a gross capital increase of $9.0m from the issue of 866,666 new shares in MagForce USA (to a US investor) has secured funding for the pivotal US prostate cancer trial. MagForce expects the first 10 patients in the trial to be treated by year-end 2018 and thus preliminary data to be available early in 2019. Prostate cancer in the US presents a significant market opportunity. The company forecasts that NanoTherm could be launched for the commercial treatment of prostate cancer patients in the US by the end of 2019 (subject to FDA approval).
EU expansion and reimbursement required in GBM
Reported revenues of €24k for H118 reflect a drop-off in remunerated GBM treatments. This reflects both the change in revenue recognition and lower number of patients treated in Germany, stemming from a transition of foreign private to reimbursed treatments, and expansion progressing slower than anticipated. With the installation of NanoActivators in Poland and other European countries outside Germany we expect a sharp increase in treatment sales. Once reimbursement discussions in Germany are concluded, we expect a recovery in sales to follow.
Financials: H118 results
MagForce reported cash and cash equivalents at 30 June 2018 of €5.3m and net debt of €10.0m (H117: €0.4m); in January, the first €10.0m tranche of a €35.0m loan facility (with the EIB) was disbursed and will enable the continued expansion into territories beyond Germany. MagForce reported net profit of €4.1m in H118 (H117: €3.0m loss), largely attributed to the one-off, non-cash gain associated with the recognition of hidden reserves in MagForce USA.
|
Historical financials
Source: MagForce accounts. Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Figures above do not include MagForce USA. |
|
||||||||
Research: Healthcare
Acacia Pharma has resubmitted a New Drug Application (NDA) to the FDA for its lead asset BARHEMSYS (repurposed amisulpride) for the management of post-operative nausea and vomiting (PONV). While the original complete response letter (CRL) received was unexpected, the issues related to deficiencies at the contract manufacturers responsible for producing the active pharmaceutical ingredient (API) and not to any other part of the application or the API itself. Within 30 days of this resubmission, the FDA will determine whether the application constitutes a Class 1 (up to two months) or Class 2 (up to six months) review. Acacia maintains that a potential launch of BARHEMSYS for PONV rescue is possible in H119. It has reported a 9M18 net loss of £10.0m, driven by preparation activities for the commercial launch of BARHEMSYS. We value Acacia at €602m or €11.3/share.